Anand Kumar/AI-Generated Image
Summary: Ion Exchange’s Q1 FY27 profit plunged as weak project economics, higher interest costs and an underutilised Roha resin plant hit earnings. Yet the stock rose, with investors looking beyond the weak quarter to a potential recovery in chemical margins, plant utilisation and business mix.
Ion Exchange had a poor start to FY27. Barring revenue, which grew by 20 per cent to Rs 701 crore, both operating profit (EBITDA) and net profit tumbled to Rs 32 crore and Rs 3 crore, respectively, in Q1. Moreover, the margin dropped to just 4.5 per cent, from nearly double digits earlier.
Interestingly, these numbers haven’t affected its share price. Rather than falling, Ion Exchange’s stock climbed about 10 per cent above its December level by the end of July. It had fallen as low as the Rs 310s in March, then bounced back. Investors, it seems, are looking past this bad quarter to what several parts of the business could earn once recent investments start generating returns.
A new way of counting the business
This year, Ion Exchange split its old ‘Engineering’ division into three parts: Treatment Solutions (large, custom water-treatment projects), Industrial Products (standard equipment) and Lifecycle Services (maintenance, spares, long-term contracts). It renamed Chemicals to Specialty Chemicals. Consumer Products remain unchanged.
The company’s management wants products, chemicals and services to make up 60 per cent of Ion Exchange, with Treatment Solutions constituting the remaining 40 per cent. The split matters because these businesses behave differently. Custom projects can run over budget and get stuck waiting on client payments. Products and services carry less of that risk.
Where Q1 FY27’s losses came from
Treatment Solutions lost Rs 17 crore, even as revenue grew 14 per cent to Rs 210 crore. Its biggest drag is a Uttar Pradesh water-supply project that depends on state government funding, which has been slow, and will likely run past this year. Ion Exchange says it is now choosier about which projects to take on, favouring safer, more technical work over cheap, high-risk contracts. A recent Rs 500 crore order from Hyundai Engineering, to supply filtration equipment for a Middle East project, is one example: a straightforward supply order, not the kind of complex site project that caused losses in the first quarter.
Specialty Chemicals, usually the company's best business, saw its margin fall from 24.5 per cent to under 10 per cent. Management says its new Roha resin plant explains roughly 6 percentage points of that drop, because the plant is running but not yet earning enough to cover its own costs. Another three to four points came from a currency gain last year that did not repeat. Raw-material costs rose too, though management says that pressure is now easing.
That still leaves a gap: EBITDA fell 49 per cent, but net profit fell 94 per cent. Two costs below EBITDA explain most of the rest. Interest costs on Ion Exchange's debt more than tripled, and depreciation jumped, both because Roha now counts as a finished asset in the accounts, well before it earns like one.
What Roha could eventually be worth
Ion Exchange expects its Roha plant to take about four years to reach full capacity. Roughly Rs 275 crore of its cost went into the core manufacturing plant. Using management's own numbers on how much revenue that kind of investment should generate, Roha could eventually produce Rs 500-550 crore a year in sales. At a margin of 18-24 per cent, in line with what Specialty Chemicals has earned in better years, that works out to roughly Rs 95-126 crore of extra profit, on top of what the rest of the division already earns. This is not a forecast. It is a sense of scale.
Roha is not just about higher volumes of the same resin. The extra capacity also lets Ion Exchange make higher-value, pharmaceutical-grade resins, an expansion management says needs know-how more than fresh capital.
The catch? Management still expects only 25 per cent utilisation this year, and admits the first four months were softer than planned. This is the number to watch most closely.
Other signs of progress, with one important correction
Industrial Products nearly tripled its profit to Rs 13 crore, on 14 per cent revenue growth. Lifecycle Services grew 28 per cent, while Consumer Products grew 33 per cent and is close to breakeven. Ion Exchange is also building longer, service-based contracts through Lifecycle Services, including a 20-year deal with Petroleum Development Oman.
The Oman deal is bigger and riskier, rather than just a simple maintenance contract. Ion Exchange has to design and build the water and sewage plants first, at a cost of roughly Rs 300 crore, before 20 years of operating revenue begins. It is a genuine growth driver, but it carries real construction risk, not just steady service fees.
Cash remains a weak spot. FY26 profit topped Rs 140 crore, but operating cash flow was negative, as money stayed tied up in unpaid bills and inventory. Separately, a subsidiary, Ion Exchange Enviro Farms, is appealing a SEBI order to repay Rs 22 crore, a small but unresolved legal risk worth tracking.
The takeaway
None of this guarantees a turnaround. Roha's ramp-up is already behind plan. The legacy projects will drag on. Cash flow is negative. If Roha fills slowly and chemical margins don't recover, Ion Exchange could simply get bigger without getting more profitable.
But if Roha fills up, chemical margins recover and new orders earn better returns, profit could grow faster than revenue, because most of the capital for that growth has already been spent. Management itself says a return to double-digit profitability is a multi-year process, not a quick fix, and that is probably the right way to read this business: less a one-quarter turnaround, more a multi-year test of whether money already spent starts generating real returns.
Watch three numbers over the next year: Roha's utilisation rate, Specialty Chemicals' margin, and the profitability of new Treatment Solutions orders. Together, they will answer the real question.
Want expert guidance on stocks like Ion Exchange?
Tracking a story like this, where the headline numbers and the underlying business tell different stories, is exactly the kind of judgment call that separates a good investment decision from a costly one. Value Research Stock Advisor gives you research-backed stock recommendations, in-depth company analysis, and ongoing coverage to help you decide when to buy, hold or exit.
Subscribe to Stock Advisor today
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
